Participant eligibility -Inclusion
-On stable medications for breathlessness over the prior one week except routine "as needed" medications -Able to provide written and dated informed consent -Moderate / severe COPD. (FEV1 30%-80% of predicted for age in spirometry performed approximately 10-15 minutes after the subject has self-administered 4 inhalations (i.e., total 400mcg) of albuterol/salbutamol via a metered dose inhaler (MDI) with a valved-holding chamber. The FEV1/FVC ratio and FEV1 percent predicted values will be calculated using NHANES III reference equations) [Hankinson 1999 ]. Subjects will have COPD which complies with the definition of the American Thoracic Society/European Respiratory Society. [Celli, 2004] . 
Participant eligibility -Exclusion
True adverse reactions to any of the administered medications.
On regular or 'as needed' opioids in the week before commencing the study and at any time during the study.
Unable to give informed consent or complete evaluation tool entries. Cognitively impaired (Mini Mental State < 24). [Folstein] Calculated creatinine clearance of < 30mls using MDRD. [Levey 1999] Known or suspected bowel obstruction (specific contra-indications in methylnaltrexone) or known or suspected GI lesions. 
